ARM011 not checked
TriArm Therapeutics (Taiwan) Limited
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ARM011 is an autologous, CD19 targeted CAR T-cell product developed on fast-in-time (FIT) platform-a non-viral, 2-day rapid manufacturing process”In the company’s words, NCT07066397 on ClinicalTrials.gov
- Tested for
- Acute Lymphoblastic Leukemia
- Main trialPhase 1
- “This is a Phase 1 study to evaluate FIT-CD19-CAR-T (ARM011) safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.”In the company’s words, NCT07066397 on ClinicalTrials.gov
Other drugs for Acute Lymphoblastic Leukemia
- TisagenlecleucelNovartis · Phase 3
- VenetoclaxAbbVie · Phase 3
- RemimazolamAcacia Pharma Ltd · Phase 2/3
- BlinatumomabAmgen · Phase 3
- OlverembatinibAscentage Pharma Group Inc. · Phase 3
- Orca-TOrca Biosystems, Inc. · Phase 3
Coming up1
- 1 Apr 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 1 Apr 2028 | A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026